


LY2183240

## Chemical Properties

CAS No. : 874902-19-9  
 Formula: C<sub>17</sub>H<sub>17</sub>N<sub>5</sub>O  
 Molecular Weight: 307.35  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
*Actual storage temperature shall be subject to the COA.*



## Biological Description

Description	LY2183240 inhibits fatty acid amide hydrolase (FAAH) activity (IC <sub>50</sub> = 12.4 nM). LY2183240 is a novel and highly effective blocker of anandamide uptake (IC <sub>50</sub> = 270 pM).
Targets(IC <sub>50</sub> )	FAAH, Autophagy
In vitro	LY2183240 increases brain anandamide concentration and exerts antinociceptive effects in the formalin model of pain, anandamide uptake Following i.p. administration in rats.

## Solubility Information

Solubility	DMSO: 65 mg/mL (211.49 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.2536 mL	16.2681 mL	32.5362 mL
5 mM	0.6507 mL	3.2536 mL	6.5072 mL
10 mM	0.3254 mL	1.6268 mL	3.2536 mL
50 mM	0.0651 mL	0.3254 mL	0.6507 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Dickason-Chesterfield AK, et al. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. *Cell Mol Neurobiol.* 2006 Jul-Aug;26(4-6):407-23.
- Sun L, et al. Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation. *Eur J Pain.* 2017 May;21(5):804-814.
- Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. *J Am Chem Soc.* 2006 Aug 2;128(30):9699-704.
- Maione S, et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. *Br J Pharmacol.* 2008 Nov;155(5):775-82.
- Pelorosso FG, et al. The endocannabinoid anandamide inhibits kinin B1 receptor sensitization through cannabinoid CB1 receptor stimulation in human umbilical vein. *Eur J Pharmacol.* 2009 Jan 5;602(1):176-9.
- Powers MS, et al. Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. *Psychopharmacology (Berl).* 2010 Dec;212(4):571-83.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481